n (%) | ||
---|---|---|
Polymyositis | Dermatomyositis | |
(n = 117) | (n = 108) | |
Females | 81 (69.2) | 75 (69.4) |
Average age of onseta | 50.4 ± 14.5 | 49.0 ± 14.1 |
Interstitial lung disease | 18 (15.4) | 19 (17.6) |
Malignancyb | 2 (1.7) | 14 (13.0) |
Antibody status | (n = 105) | (n = 101) |
Myositis-specific antibodies | ||
Jo-1 | 24 (22.9) | 22 (21.8) |
PL-7 | 1 (1.0) | 0 |
PL-12 | 0 | 1 (1.0) |
EJ | 0 | 1 (1.0) |
OJ | 1 (1.0) | 1 (1.0) |
KS | 1 (1.0) | 1 (1.0) |
Any of the abovec | 27 (25.7) | 25 (24.7) |
Mi-2d | 1 (1.0) | 17 (16.8) |
SRP | 5 (4.8) | 2 (2.0) |
Myositis-associated antibodies | ||
U1-RNP | 5 (4.8) | 8 (7.9) |
U3-RNP | 0 | 2 (2.0) |
Ku | 0 | 2 (2.0) |
PM-Scl | 5 (4.8) | 6 (5.9) |
None of the above autoantibodies | 62 (59.1) | 45 (44.5) |